Last reviewed · How we verify
Tezspire
At a glance
| Generic name | Tezspire |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Target | Thymic stromal lymphopoietin |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Severe asthma
Common side effects
- Pharyngitis
- Arthralgia
- Back pain
- Injection site reactions
Serious adverse events
- Serious cardiac adverse events
- Major adverse cardiovascular events (MACE)
Key clinical trials
- TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
- Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
- A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (PHASE3)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Tezspire Cardiac Events PASS
- Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS) (PHASE2)
- A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects (PHASE1)
- Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tezspire CI brief — competitive landscape report
- Tezspire updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI